Evidence map›Paper›PMID 24474275›Full record

ArticleInvestigative ophthalmology & visual science2014

Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells.

Guadalupe Villarreal, Ayan Chatterjee, Sarah S Oh, Dong-Jin Oh, Douglas J Rhee

Open access · bronzeAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Review
  7. Article
  8. Identification of Gene Changes Induced by Dexamethasone in the Anterior Segment of the Human Eye Using Bioinformatics Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Matricellular proteins in the trabecular meshwork: review and update.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Guadalupe VillarrealDepartment of Ophthalmology, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, Massachusetts.
Ayan Chatterjee
Sarah S Oh
Dong-Jin Oh
Douglas J Rhee
Massachusetts Eye and Ear Infirmary · USHarvard University · US

Funding

P30 Core Grant for Vision ResearchP30EY014104 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Eric A Pierce · 2002 to 2026
$15.1M
Matricellular Proteins in Trabecular Meshwork Increase Intraocular PressureR01EY019654 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI RHEE, DOUGLAS J · 2009 to 2020
$3.5M
Howard Hughes Medical InstituteNEI NIH HHS EY 014104NEI NIH HHS EY 019654-01NEI NIH HHS P30 EY014104NEI NIH HHS R01 EY019654
6 · The paper itself

Abstract

purposeStatins have been shown to increase aqueous outflow facility. The matricellular protein SPARC (secreted protein acidic and rich in cysteine) is a critical mediator of aqueous outflow and intraocular pressure (IOP). Here, we examine the effects of lovastatin on SPARC expression in trabecular meshwork (TM) cells, exploring the molecular mechanisms involved.

methodsPrimary cultured human TM cells were incubated for 24, 48, and 72 hours with 10 μM lovastatin. In separate cultures, media was supplemented with either farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP) for the duration of the 72-hour time point experiment. Trabecular meshwork cells were also pretreated for 24 hours with lovastatin followed by 24-hour stimulation with 3 ng/mL TGF-β2. Cell lysates and media were harvested and relative mRNA and protein level changes were determined. Krüppel-like factor 4 (KLF4) localization in normal human anterior segments was examined by immunofluorescence. Adenovirus expressing human KLF4 was used and relative changes in SPARC mRNA and protein levels were assessed.

resultsIncubating TM cells with lovastatin suppressed SPARC mRNA and protein levels. This effect was reversed upon media supplementation with GGPP but not FPP. Pretreating cells with lovastatin inhibited TGF-β2 induction of SPARC. The KLF4 transcription factor was expressed throughout the TM and the inner and outer walls of Schlemm's canal. Lovastatin treatment upregulated KLF4 mRNA and protein levels. Overexpression of KLF4 downregulated SPARC expression.

conclusionsCollectively, our data identify lovastatin as an important pharmacological suppressor of SPARC expression in TM cells, and provide further insight into the molecular mechanisms mediating statin enhancement of aqueous outflow facility.

Indexed as

AdultAgedCells, CulturedGene Expression RegulationGlaucomaHumansHydroxymethylglutaryl-CoA Reductase InhibitorsImmunoblottingKruppel-Like Factor 4LovastatinMiddle AgedOsteonectinReal-Time Polymerase Chain ReactionRNATrabecular MeshworkHydroxymethylglutaryl-CoA Reductase InhibitorsKLF4 protein, humanKruppel-Like Factor 4LovastatinOsteonectinRNASPARC protein, humanglaucomaKLF4SPARCstatinsTGF-β2trabecular meshwork

Identifiers

PMID24474275
PMCPMC4586968
OpenAlexW2074736871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.